Characterizing medical mistrust (MM) in a socio-demographically diverse sample of patients with cancer.

Authors

null

Cindy Park

Temple University, Lewis Katz School of Medicine, Philadelphia, PA

Cindy Park , Sarah B Bass , Karen J Ruth , Yana Chertock , Katie J Singley , Caseem C Luck , Malak Abuhillo , Aleeha Khan , Shreya Gowda , Erin M Holland , Elizabeth Knight , Shreya Verma , Alexandru-Mircea Rotaru , Abeeda Hussain-Kasim , Agostina Waisfeld , Michael J. Hall

Organizations

Temple University, Lewis Katz School of Medicine, Philadelphia, PA, Temple University College of Public Health, Philadelphia, PA, Biostatistics and Bioinformatics Core, Fox Chase Cancer Center, Philadelphia, PA, Department of Clinical Genetics, Fox Chase Cancer Center, Philadelphia, PA, Fox Chase Cancer Center, Philadelphia, PA

Research Funding

U.S. National Institutes of Health
U.S. National Institutes of Health, ECOG ACRIN

Background: Genetic and genomic testing are increasingly recognized as essential to high quality cancer care. Despite expanded eligibility for testing in recent years, barriers to genomic medicine persist. Notably, growing political and social mistrust risks negatively impacting views of medical institutions, medical professionals and complex technologies, and could undermine acceptance of genetic/genomic testing to guide treatment and identify risk in families. Prior studies have documented disparities and increased MM of genetic counseling and testing among underserved minorities which have been associated with delays or avoidance to care. We sought to identify individual characteristics associated with MM among cancer patients. Methods: A cross-sectional survey of cancer pts from the Fox Chase Cancer Center (FCCC) Burholme Campus (n=105, mixed urban/suburban, primarily insured) and Broad street campus (n=95, primarily urban underserved population) was conducted from 6/22-12/22, using a maximum variation (purposeful) sampling approach. Surveys queried MM using the LaVeist MM Index (MMI, range 0-10, measures healthcare/institution MM) and the Thompson Group Based MM Scale (GBMMS, range 1-5, measures race/ethnic specific MM; suspicion, discrimination, and lack of support subscales). Demographic and disease factors, as well as psychosocial measures (general/genetic health literacy, social support, self-advocacy, conspiratorial thinking, relationship with doctor, and trust in information sources) were also assessed. Medical decision making preference and health literacy were assessed with single validated items. The study was approved by the FCCC IRB #22-8003. Results: Participants had a median age of 62 yrs (range 25-91); 62% were female, 47% African American (AA), 15% Hispanic, 42% married, 47% high school graduate or less, 52% had household income <$50K/yr. Breast (28%), colorectal (16%), and GYN/GU (12%) cancers were the most commonly reported, and 23% reported >1 previous cancer diagnosis. Mean GBMMS was 2.11 (SD 0.80) and mean MMI was 4.63 (SD 1.54). See the table for significant associations. Conclusions: High levels of healthcare institution and race-based MM are associated with socio-demographic vulnerabilities, putting the most vulnerable cancer patients at high risk of making poor health decisions.

PredictorMMI
Healthcare institution mistrust
GBMMS
Race-based medical mistrust
Comparators
AgeNSp=0.04Younger>older
Race/ethnicityp=0.04p<0.001AA>Hispanic>White
Stage (Early/Late/Unsure)p=0.04NS“Unsure” highest
Educationp=0.03NS< high school highest
Insurance type p=0.04NSMedicaid highest
Annual household incomeNSp=0.05< $25K highest
Site (urban/suburban)NSp=0.03Urban higher
Health literacyNSNS
Medical decision making preferencep=0.0015p=0.07“I make the decisions without MD input” highest

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Prevention, Risk Reduction, and Hereditary Cancer

Track

Prevention, Risk Reduction, and Genetics

Sub Track

Germline Genetic Testing

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 10551)

DOI

10.1200/JCO.2023.41.16_suppl.10551

Abstract #

10551

Poster Bd #

184

Abstract Disclosures

Similar Abstracts

Abstract

2023 ASCO Annual Meeting

National Coalition for Cancer Survivorship State of Survivorship Survey.

First Author: Shelley Fuld Nasso

Abstract

2023 ASCO Quality Care Symposium

Access to radiotherapy in Hispanic and Latinx populations in the United States: An update.

First Author: Nicholas Peter Verdini